|
News
CritiTech Consolidates R&D and
Commercial Operations
July 26, 2005
FOR IMMEDIATE RELEASE
Contact: Sam Campbell, CritiTech CEO and president, (785)
841-7120
LAWRENCE, Kan.- CritiTech, Inc., announced that it has completed
the transfer of its technology and R&D laboratory operations
from the Higuchi Biosciences Center at the University of Kansas
to its new facility located in the West Lawrence Laboratories
at 4950 Research Park Way, Lawrence, Kansas. The commercial
operation of the company was established at 4950 Research
Park Way in mid year 2004. The addition of Jahna Howell as
Director of Laboratory Operations has enabled the company
to consolidate its R&D and commercial activity into a
single location and to expand its in-house drug development
program. Dr. Charles Decedue, Executive Director of the Higuchi
Biosciences Center and the Chairman of the CritiTech Scientific
Advisory Board, stated “we are pleased to see CrtiTech’s
continued growth to the operational phase of their business
plan and proud to have been a part of that growth and development.
We are confident that the addition of Jahna Howell will complete
the transfer of supercritical fluid, nanoparticle technology
from the Higuchi Biosciences Center to CritiTech. Equally,
we look forward to future work with CritiTech as a corporate
partner in future drug development projects.”
CritiTech provides critical drug delivery
and development technology for the pharmaceutical industry
through its patented nanoparticle production technology originally
developed at the University of Kansas. In addition, the company
uses its proprietary technology to coat implantable medical
devices such as cardiac stents. This enables devices to be
implanted with less concern about restenosis and rejection.
|
